Business
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
SEATTLE , May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold an aggregate of 21,607,878 shares of the company’s common stock through its at-the-market (“ATM”) facility established through TD Securities (USA) LLC for net proceeds of approximately $69 million. The investment, including participation based on interest received from RA Capital Management, combined
About this update from Sana Biotechnology, Inc.
[{"type":"image","alt":"Sana Biotechnology, Inc","displaySize":"","headline":null,"caption":"Sana Biotechnology, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/c8ec5ce7c1d4da77d92cdc607ff85c4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1FAbLyhhxj0MOkOtuA91gA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOQ--/https://media.zenfs.com/en/globenewswire.com/c8ec5ce7c1d4da77d92cdc607ff85c4e","width":300,"height":85},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/1FAbLyhhxj0MOkOtuA91gA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOQ--/https://media.zenfs.com/en/globenewswire.com/c8ec5ce7c1d4da77d92cdc607ff85c4e","width":300,"height":85}},"lazy":false},{"type":"text","content":"SEATTLE , May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold an aggregate of 21,607,878 shares of the company’s common stock through its at-the-market (“ATM”) facility established through TD Securities (USA) LLC for net proceeds of approximately $69 million. The investment, including participation based on interest received from RA Capital Management, combined with the previously announced unrelated $25 million investment from the Mayo Clinic, brings the total capital raised since the end of the first quarter of 2026 to approximately $94 million and extends the company’s expected cash runway to mid-2027.","length":749,"tagName":"p"},{"type":"text","content":"The shares of common stock described above were sold by the company pursuant to an automatically effective shelf registration statement on Form S-3ASR (File No. 333-293981), including the ATM prospectus supplement, filed by the company with the SEC on March 3, 2026. The ATM prospectus supplement and the accompanying prospectus may be obtained from TD Securities (USA) LLC, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected]. Electronic copies of the ATM prospectus supplement and the accompanying prospectus are also available on the SEC's website at http://www.sec.gov.","length":676,"tagName":"p"},{"type":"text","content":"This press release does not constitute an offer to sell or a solicitation of an o...